Valuation -- 5/10
MRK trades at ~16.6x trailing earnings, which looks reasonable against large-cap pharma peers --
but the metric is misleading. FY2026 GAAP EPS guidance of $5.00-$5.15 (including ~$3.65 Cidara
charge) puts the forward multiple at ~23-24x on guided numbers. The defining overhang is the
largest single-product LOE in pharmaceutical history: Keytruda (~$32-35B peak revenue) faces IV
patent expiry in Dec 2028, with IRA negotiated pricing effective 2029. Management points to a
$70B non-risk-adjusted pipeline opportunity, but that remains substantially unproven. Near-term
execution is solid -- Keytruda growing, Winrevair ramping impressively -- but the sheer magnitude
of the cliff creates a genuinely bifurcated risk/reward profile.
Weight: 15%
Trailing P/E
16.6x
TTM EPS ~$7.28
Forward P/E (FY26 Guide)
~23-24x
GAAP EPS $5.00-$5.15 guided
Dividend Yield
2.81%
Well-covered for now
Market Cap
$298.8B
Price $120.87, near 52-wk high
Valuation context
| Metric | MRK | Context |
|---|---|---|
| Price | $120.87 | Up ~65% from 52-wk low; near 52-wk high |
| Trailing P/E | 16.6x | TTM EPS ~$7.28; looks cheap but peak earnings |
| Forward P/E (FY26 Guide) | ~23-24x | GAAP EPS $5.00-$5.15 (incl. ~$3.65 Cidara charge) |
| Revenue (FY2025A) | ~$64.5B | FY26 guide: $65.5B-$67.0B (+2-4%) |
| Keytruda (FY2025A) | ~$31.7B | ~49% of total revenue; peak ~$32-35B expected |
| Winrevair (Q4 25 annualized) | ~$1.9B | Peak estimates $5-7B; excellent ramp trajectory |
| Gardasil (FY2025A) | ~$5.2B | Down ~39% YoY from $8.6B; China destocking |
| Dividend Yield | 2.81% | Well-covered; provides downside support |
Peer multiples
| Company | Forward P/E | Notes |
|---|---|---|
| MRK (Merck) | ~16.6x TTM / ~23-24x FY26 | Cheap on TTM, expensive on guided EPS |
| LLY (Eli Lilly) | 27.6x | Premium for GLP-1 growth |
| JNJ (Johnson and Johnson) | 18.8x | Diversified, defensive |
| ABBV (AbbVie) | 15.7x | Post-Humira recovery |
| BMY (Bristol-Myers Squibb) | 9.5x | Deep LOE discount (Eliquis/Opdivo) -- where MRK could compress |
| PFE (Pfizer) | ~8.5x | COVID hangover, restructuring |
BMY at 9.5x -- further into its own LOE cycle -- is the marker of where MRK could compress if
the pipeline fails to offset the Keytruda cliff. The trailing 16.6x is not a value signal when
the earnings base is at peak.
Consensus estimates
| Metric | FY2025A | FY2026E | FY2027E |
|---|---|---|---|
| Revenue | ~$64.5B | $65.5-$67.0B (guide) | Street ~$68-70B |
| EPS (Adj) | ~$7.28 | $5.00-$5.15 (guide) | Street ~$10.00-$10.05 |
| Keytruda | ~$31.7B | ~$32.7B (peak) | Declining post-LOE |
The wide gap between company EPS guidance ($5.00-$5.15) and some street estimates ($6.16 Zacks)
reflects confusion over one-time Cidara charges. The underlying business is guiding ~4-8% organic
revenue growth ex-LOE products. Data sourced from Daloopa.
Key product revenue trends (quarterly, $M)
| Product | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|
| Keytruda | $6,947 | $7,270 | $7,429 | $7,836 | $7,205 | $7,956 | $8,142 | $8,372 |
| Gardasil | $2,249 | $2,478 | $2,306 | $1,550 | $1,327 | $1,126 | $1,749 | $1,031 |
| Winrevair | -- | $70 | $149 | $200 | $280 | $336 | $360 | $467 |
Keytruda grew +7.4% YoY to ~$31.7B (FY2025), still accelerating into the cliff. Winrevair annualizing
at ~$1.9B with 9,100+ patients on therapy. Gardasil declined ~39% YoY on China destocking -- a
significant secondary concern. Data sourced from Daloopa.
Catalysts
| # | Catalyst | Timing | Probability | Impact |
|---|---|---|---|---|
| 1 | Keytruda Qlex (SC) adoption reaches 30-40% | Through 2028 | High | High |
| Locks in patients pre-biosimilar entry; extends franchise life beyond IV patent expiry. | ||||
| 2 | Winrevair label expansion (heart failure) | ACC 2026 / Phase 3 | Medium | High |
| Could double TAM from $5-7B to $10B+. Cadence data at ACC 2026 is a key catalyst. | ||||
| 3 | Tulisokibart (TL1A) Phase 3 in UC | H2 2026 readout | Medium | High |
| First/best-in-class TL1A inhibitor; multi-billion dollar opportunity in IBD. | ||||
| 4 | Keytruda IV patent defense to Nov 2029 | Ongoing litigation | Medium | High |
| Extra ~12 months of exclusivity worth $8-10B incremental revenue if method-of-use patents hold. | ||||
| 5 | Islatravir + lenacapavir (HIV) | 2026 data | Medium | Medium |
| First weekly oral HIV regimen; large total addressable market. | ||||
| 6 | ADC pipeline (sac-TMT, I-DXd) | Phase 3 data 2027 | Medium-Low | Medium |
| Key to replacing Keytruda oncology revenue long-term. Multiple programs in development. | ||||
| 7 | Capvaxive (pneumococcal vaccine) ramp | Ongoing | Medium | Medium |
| $279M in 2025; could reach $2-3B at peak. Helps diversify away from Keytruda dependence. | ||||
| 8 | $70B pipeline opportunity de-risked by 2027 | Per CEO Davis | Medium | Transformational |
| Would fundamentally change the narrative if proven. 20+ Phase 3 programs provide breadth. | ||||
Key risks
| # | Risk | Severity | Timing | Mitigation |
|---|---|---|---|---|
| 1 | Keytruda LOE / biosimilar entry | CRITICAL | Dec 2028 (possibly Nov 2029) | SC Keytruda Qlex, patent defense, label expansion |
| 2 | Revenue cliff magnitude (~$30B+ at risk) | CRITICAL | 2029-2032 | $70B pipeline; consensus sees Keytruda falling to ~$7B by 2032 |
| 3 | IRA negotiated pricing on Keytruda | HIGH | 2029 (delayed from 2028) | Limited -- structural policy risk |
| 4 | Gardasil China deterioration | HIGH | Ongoing | Diversification into other markets; vaccine pipeline |
| 5 | Pipeline clinical failures | HIGH | 2026-2027 readouts | Breadth of pipeline (20+ Phase 3 programs) |
| 6 | Acquisition overpay risk | MEDIUM-HIGH | Ongoing | CEO commits to $15B sweet spot, disciplined approach |
| 7 | Multiple compression toward BMY levels | MEDIUM-HIGH | As LOE approaches | Could see PE compress from ~16x to 10-12x |
| 8 | Winrevair competition | MEDIUM | 2027+ | First-mover advantage; differentiated mechanism |
| 9 | Januvia/Janumet generic erosion | MEDIUM | 2026 (now) | Already in guidance; ~$4-5B headwind largely priced |
| 10 | Cidara acquisition integration | MEDIUM | 2026-2027 | ~$9B one-time charge already guided |
Scenario analysis
| Scenario | Prob. | Price Range | Implied Return | Key Assumptions |
|---|---|---|---|---|
| Bull | 25% | $145-$165 | +20% to +37% | Qlex converts 40%+, patent defense to Nov 2029, Winrevair $5B+, tulisokibart succeeds, re-rates to 18-20x |
| Base | 50% | $100-$130 | -17% to +8% | Cliff partially mitigated, revenue troughs ~$55-58B in 2030-31, stock range-bound until 2027 visibility |
| Bear | 25% | $70-$85 | -30% to -42% | Biosimilars aggressive, SC conversion stalls at 20%, pipeline attrition, Gardasil to $4B, PE compresses to 9-10x |
At $120.87, MRK sits in the upper half of the base case range. The asymmetry is modestly negative --
bear case downside (-30 to -42%) exceeds bull case upside (+20 to +37%). Investors are being asked
to underwrite a pipeline transition rarely achieved at this magnitude in pharma history.
Bull and bear scenarios
Bull Case ($145-$165, +20-37% upside)
- Keytruda Qlex converts 40%+ of patients; biosimilar uptake slower than feared
- Patent defense extends exclusivity to Nov 2029
- Winrevair reaches $5B+ by 2029; tulisokibart succeeds in IBD
- Pipeline delivers 3-4 additional $2-5B assets by 2030
- Stock re-rates to 18-20x as cliff anxiety fades
- M&A fills gaps at disciplined prices ($10-15B sweet spot)
Bear Case ($70-$85, -30-42% downside)
- Biosimilars launch 2028 with aggressive pricing; SC conversion stalls at 20%
- Pipeline attrition hits key assets (TL1A, ADCs)
- Gardasil continues declining toward $4B
- Multiple compresses to BMY-like 9-10x on shrinking earnings
- IRA pricing erodes Keytruda profitability ahead of LOE
- Acquisition integration stumbles; overpay destroys value
The defining question: can Merck bridge the Keytruda cliff?
Keytruda represents ~$30B+ in revenue at risk -- approximately 45% of total company revenue.
This is the largest single-product LOE in pharmaceutical history. Management has the broadest
pipeline in the company history (20+ Phase 3 programs, $70B non-risk-adjusted opportunity), and
Winrevair is ramping impressively. But the math is daunting: replacing even half of Keytruda
requires multiple blockbusters to succeed simultaneously. The score of 5 reflects this genuine
knife-edge -- real catalysts exist but the magnitude of the cliff risk and the below-consensus
2026 guidance keep the concern level elevated. Watchlist, not actionable at $120.87.
Score rationale: 5/10
| Factor | Assessment |
|---|---|
| Near-term execution | Strong -- Keytruda growing, Winrevair ramping, beat Q4 |
| Valuation support | Moderate -- 16.6x trailing looks fair, but forward earnings declining |
| Catalyst density | High -- Multiple Phase 3 readouts in 2026-2027 |
| Risk magnitude | Very High -- Largest LOE in pharma history, ~45% of revenue |
| Management credibility | Above average -- Strong BD track record, transparent on cliff |
| Dividend support | Solid -- 2.81% yield, well-covered for now |
| Earnings trajectory | Negative -- FY26 EPS guided well below FY25 (one-time items + LOE products) |
Analysis as of April 2026. Valuation data sourced from Daloopa, company filings, and consensus estimates.